| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Brian Jg Pereira is Director at PROK. Brian Jg Pereira's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Brian Jg Pereira has 17 Form 4 filings on record from February 2019 to August 2026, across 3 companies: Director at ProKidney (PROK), 2022–2026; Director at KalVista Pharmaceuticals (KALV), 2019–2025; Executive Chairman at Abeona Therapeutics (ABEO), 2020.
The 28 reported transactions were 14 option or other derivative awards, 10 open-market sales and 4 conversions.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $3.0M.
The largest open-market sale was 757,162 shares of PROK at an average $2.49 on November 13, 2025, about $1.9M.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.